Treatment of adults with overweight or obesity with or without weight-related comorbidities
Patent Information
- Application Number
- HK62026123359
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-15
- Filing Date
- 2026-05-13
- Publication Date
- 2026-07-31
Smart Images
Figure 00000098_0000 
Figure 00000099_0000 
Figure 00000101_0000
Abstract
Description
Abstract This disclosure provides a method for treating overweight or obese patients with or without type 2 diabetes. The treatment comprises administering a dual agonist of GLP-1 and GIP receptors.
Claims
CLAIMS1. A method of managing weight, improving glycemic control, and / or increasing insulin sensitivity in an overweight or obese adult patient in need thereof, comprising administering by subcutaneous injection to the patient a compound of Formula I, or a pharmaceuticallywherein the compound is administered at a body weight-independent dose of about2.0 mg to about 25 mg.
2. The method of claim 1, wherein the patent has a BMI of >25 kg / m2, >27 kg / m2, >30 kg / m2, >35 kg / m2, or >40 kg / m2.
3. The method of claim 1, wherein the patient is obese.
4. The method of claim 3, wherein the patient does not have type 2 diabetes mellitus, or is prediabetic.
5. The method of claim 3, wherein the patent has type 2 diabetes mellitus.
6. The method of any one of claims 1-5, wherein the patient has one or more weight- related comorbidities, optionally prediabetes, hypertension, or dyslipidemia.95SUBSTITUTE SHEET (RULE 26)7. The method of any one of claims 1-6, wherein the administering step is repeated once every week, once every two weeks, once every four weeks, or once every month.
8. The method of any one of the preceding claims, wherein the dose is about 5, 6, 7.5, 8, 12, 16, 17, 22, or 24 mg.
9. The method of any one of the preceding claims, wherein the dose is up-titrated over a period of 3 weeks to 30 weeks.
10. The method of claim 9, wherein the starting dose for the up-titration is about 5 mg or about 8 mg.
11. The method of claim 10, wherein the maximum dose for the up-titration is about 22 or 24 mg.
12. The method of any one of the preceding claims, wherein the patient receives an additional therapy for overweight or obesity, optionally wherein the additional therapy is diet therapy or exercise therapy.
13. The method of any one of the preceding claims, wherein administration of the compound results in reduction of visceral adiposity and / or HbAlc level in the patient.
14. A compound for use in a method of any one of claims 1-13, wherein the compound is of Formula I, or a pharmaceutically acceptable salt or ester thereof:SUBSTITUTE SHEET (RULE 26)15. Use of a compound for the manufacture of a medicament for use in a method of any one of claims 1-13, wherein the compound is of Formula I, or a pharmaceutically acceptable salt or ester thereof:
16. An article of manufacture for use in a method of any one of claims 1-13, wherein the article of manufacture comprises one or more units of said dose.
17. The article of manufacture of claim 16, wherein the article of manufacture comprises a syringe or an injector, optionally a single-use syringe or injector.97SUBSTITUTE SHEET (RULE 26)